DIRS.INFO The most relevant business & tech news

☆ Indivior CEO Mark Crossley on combatting the opioid crisis with new drugs
▼ + stars: | 2024-05-24 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIndivior CEO Mark Crossley on combatting the opioid crisis with new drugsMark Crossley, Indivior CEO, joins 'Squawk Box' to discuss what Indivior does, how much the company's drugs costs, and usage of the company's drugs.

Persons: Mark Crossley Organizations: Indivior

☆ Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.

Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior

☆ Commodity-linked stocks drag FTSE 100 lower, Indivior lifts midcaps
▼ + stars: | 2023-10-23 | by ( ) www.reuters.com time to read: +1 min

REUTERS/Toby Melville/File photo Acquire Licensing RightsSummaryCompanies FTSE 100 off 0.1%, FTSE 250 adds 0.1%Oct 23 (Reuters) - The UK's FTSE 100 slipped on Monday as rising government bond yields and losses in commodity-linked stocks kept equities under pressure, while Indivior shares boosted the midcap index on a lawsuit settlement. The commodity-focused FTSE 100 (.FTSE) was down 0.1% as of 7:08 GMT, while the mid-cap FTSE 250 (.FTMC) edged 0.1% higher. Precious metal miners (.FTNMX551030) lost 1.0% after gold prices slipped as U.S. dollar and Treasury yields strengthened. Indivior (INDV.L) shares added 7.0% after the drugmaker said it would pay $385 million to settle a lawsuit. Investors will be on the lookout for a slew of banks reporting results throughout the week with major lender Barclays (BARC.L) scheduled to post results on Tuesday.

Persons: Toby Melville, Khushi Singh, Janane Organizations: London Stock Exchange, REUTERS, FTSE, Treasury, pharma, Barclays, Meta, Microsoft, Thomson Locations: Canary Wharf, London, Britain, Israel, Bengaluru

Aug 21 (Reuters) - Indivior (INDV.L) has agreed to pay $30 million to settle a class action lawsuit filed in a U.S. court by health plans accusing the drugmaker of illegally suppressing generic competition for its opioid addiction treatment Suboxone. The settlement, disclosed on Saturday in a filing by lawyers for the health plans in federal court in Philadelphia, must still be approved by a judge. Indivior is still facing claims by drug wholesalers that bought Suboxone from the Virginia-based company directly, with a trial scheduled in October. Lawyers for the health plans did not immediately respond to requests for comment. Indivior agreed in June to pay $102.5 million to settle related claims by 41 U.S. states and Washington, D.C.

Persons: Indivior, Mark Crossley, Suboxone, Brendan Pierson, Will Dunham, Alexia Garamfalvi Organizations: U.S, D.C, U.S . Centers for Disease Control, Thomson Locations: U.S, Philadelphia, Virginia, Washington, United States, New York

☆ Morgan Stanley picks ‘particularly high conviction’ global stocks it says the rest of the market is missing
▼ + stars: | 2023-07-21 | by ( Lucy Handley | ) www.cnbc.com time to read: +1 min

Morgan Stanley has named several buy-rated global stocks it expects to beat the market. "We expect Ozempic to drive a further upgrade to guidance before the 2Q results," the analysts wrote — the company reports on Aug. 10. Other drugmakers the bank is positive on are Grifols , where the bank expects a "solid performance," and Indivior , which is set for a "strong quarter," Morgan Stanley said. French materials manufacturer Saint-Gobain is also a Morgan Stanley pick, with the bank saying that consensus has not yet priced in its management's optimism on margins discussed at its annual general meeting last month. "While another positive beat ratio looks likely for 2Q23, a slowdown in global and European economic momentum suggests that the magnitude of the said beat will be closer to normal levels," they added.

Persons: Morgan Stanley, Giorgio Magagnotti Organizations: Novo Nordisk, Deutsche Telekom, . Energy Locations: Germany

☆ Indivior CEO Mark Crossley on company mission: We help people suffering from addiction
▼ + stars: | 2023-06-12 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIndivior CEO Mark Crossley on company mission: We help people suffering from addictionIndivior CEO Mark Crossley joins 'Squawk Box' to discuss the company's mission, demand for substance abuse treatment, the opioid epidemic, and more.

Persons: Mark Crossley

☆ China IPOs are uncoupling from Wall Street too
▼ + stars: | 2023-06-12 | by ( ) www.reuters.com time to read: +2 min

Increasingly it is detaching from Wall Street too. Nonetheless, the Shanghai Stock Exchange will hold a hearing for the deal on Friday, per Refinitiv’s IFR. Syngenta is a pillar in Beijing’s strategy to shore up food security and will use the deal to pay down debt. The landmark IPO coincides with signs that Wall Street’s small position in the market is shrinking further. Syngenta’s blockbuster IPO will be an awkward new milestone for Wall Street already facing life in China’s second tier.

Persons: Beijing’s, It’s, Dealogic, Xavier Niel, Pete Sweeney, Thomas Shum Organizations: Reuters, Agricultural Bank of, Shanghai Stock Exchange, HK, BOC, Citic Securities, Twitter, Brookfield, Thomson Locations: MUMBAI, Agricultural Bank of China’s, Hong Kong, China’s, Una

☆ Brookfield gets some M&A help from Gulf friends
▼ + stars: | 2023-06-09 | by ( ) www.reuters.com time to read: +2 min

LONDON, June 9 (Reuters Breakingviews) - Brookfield Asset Management (BAM.TO) has won its payments race. The Canadian investment group’s 2.2 billion pound bid for London-listed payments provider Network International (NETW.L) was enough to see off a rival pitch from CVC and Francisco Partners. They’ve also endorsed a plan to merge Dubai-based Network International with domestic peer Magnati, a former unit of FAB. If Network International alone can grow revenues at a 15% annual clip and reach a margin of 44% from the current 41%, EBITDA could hit $388 million by 2028. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Brookfield, They’ve, EBITDA, Pamela Barbaglia, Xavier Niel, George Hay, Streisand Neto Organizations: Reuters, Brookfield Asset Management, London, Network, Francisco Partners, Abu Dhabi Bank, Abu, Abu Dhabi Developmental Holding Company, FAB, ACI, Brookfield, Twitter, Thomson Locations: Abu Dhabi, Saudi, Dubai

☆ UBS’s state aid is a disaster insurance policy
▼ + stars: | 2023-06-09 | by ( ) www.reuters.com time to read: +2 min

LONDON, June 9 (Reuters Breakingviews) - Sergio Ermotti has a taxpayer safety net, but it only kicks in if things get really bad. The state will eat 9 billion Swiss francs ($10 billion) of losses on certain assets once UBS has swallowed an initial 5 billion Swiss francs. The actual contract, despite being 94 pages long, is missing the most important number: how many assets are covered by the agreement. UBS in mid-May said it would write down the value of Credit Suisse’s assets by $10 billion. To breach its initial loss threshold, the assets would have to fall 11% below their already discounted value.

Persons: Sergio Ermotti, Liam Proud, Xavier Niel, George Hay, Oliver Taslic Organizations: Reuters, UBS, Credit Suisse, Finance, Suisse’s, Twitter, Toyota, Thomson

☆ Xavier Niel offers risky alternative for sick GAM
▼ + stars: | 2023-06-08 | by ( ) www.reuters.com time to read: +2 min

LONDON, June 8 (Reuters Breakingviews) - French billionaire Xavier Niel is asking investors to have one last flutter on GAM (GAMH.S). GAM investors will receive shares in Liontrust worth around 0.5% of the target company’s assets under management back in May, and even less now. If all goes well, GAM’s current investors could still keep a much larger share of the upside than they would with the Liontrust deal. The risk, however, is that GAM’s turnaround proves hard, cost cuts are more expensive and damaging, and the group keeps losing assets or staff. Moreover, it’s plausible that Niel wins enough backing to block the deal, but not enough to replace the board, leaving GAM in limbo.

Persons: Xavier Niel, Niel, Bruellan, manager’s, Neil Unmack, Liam Proud, Streisand Neto Organizations: Reuters, Liontrust Asset Management, Twitter, Toyota, Thomson Locations: Liontrust

The pan-European STOXX 600 index (.STOXX) ended 0.4% lower after a survey showed the U.S. services sector barely grew in May, while factory orders rose less than expected. "There's a bit of profit taking after some of the moves we've had recently," said Steve Sosnick, chief strategist at Interactive Brokers. "The economic reports that we've gotten around the world (signal) a somewhat slowing economy." Shares of Indivior Plc (INDV.L) jumped 7.8% to top the STOXX 600 index after the drugmaker agreed to pay $102.5 million to settle a lawsuit for its opioid addiction treatment Suboxone. Reporting by Shreyashi Sanyal in Bengaluru; Editing by Sherry Jacob-Phillips, Dhanya Ann Thoppil and Richard ChangOur Standards: The Thomson Reuters Trust Principles.

Persons: we've, Steve Sosnick, Christine Lagarde, Joachim Nagel, Shreyashi Sanyal, Sherry Jacob, Phillips, Dhanya Ann Thoppil, Richard Chang Organizations: PMI, Interactive, U.S . Federal, European Central Bank, Amazon.com Inc, Indivior Plc, Trendyol, Viaplay, Volvo, Copenhagen Stock Exchange, Thomson Locations: U.S, Alibaba, Swedish, Sweden, Bengaluru

☆ European shares open flat; London leads on oil boost
▼ + stars: | 2023-06-05 | by ( ) www.reuters.com time to read: +1 min

June 5 (Reuters) - European shares opened flat on Monday as markets failed to catch the tailwind from a bounce seen last week, while London stocks led regional gains following upbeat performances by energy firms on the back of higher oil prices. The pan-European STOXX 600 index (.STOXX) held its ground at 462.46 points, while London's FTSE 100 (.FTSE) index led gains with a 0.5% climb. The European oil & gas sector index (.SXEP) rose 1%, buttressed by stronger oil prices after top global exporter Saudi Arabia pledged to cut production by another 1 million barrels per day from July. Shares of Indivior Plc (INDV.L) surged 11% to top the STOXX 600 Index after the drugmaker agreed to pay $102.5 million to settle a lawsuit for its opioid addiction treatment Suboxone. Reporting by Shreyashi Sanyal in Bengaluru; Editing by Sherry Jacob-PhillipsOur Standards: The Thomson Reuters Trust Principles.

Persons: Shreyashi Sanyal, Sherry Jacob, Phillips Organizations: FTSE, Saudi, Markets, U.S . Federal, Indivior Plc, Thomson Locations: London, Saudi Arabia, U.S, Bengaluru

☆ Indivior opioid settlement makes purer M&A case
▼ + stars: | 2023-06-05 | by ( ) www.reuters.com time to read: +2 min

LONDON, June 5 (Reuters Breakingviews) - Indivior (INDV.L) is one step closer to becoming a takeover target. Litigation risks have weighed down Indivior in the years following the company’s spinoff from Reckitt Benckiser (RKT.L) in 2014. The group still has lawsuits to settle over the same charges with insurers and patients. With its litigation risks easing, Indivior could soon lure larger cash rich pharmaceutical companies keen to access a market that is sadly showing no signs of decline. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Reckitt, Roche, Indivior, Aimee Donnellan, Neil Unmack, Streisand Neto Organizations: Reuters, Suboxone, AstraZeneca, U.S . Centers for Disease Control, Twitter, Toyota, Thomson Locations: U.S

Companies Indivior PLC FollowJune 2 (Reuters) - Indivior Plc (INDV.L) said on Friday it agreed to pay $102.5 million to settle a lawsuit by dozens of U.S. states accusing it of illegally suppressing generic competition for its opioid addiction treatment Suboxone. Suboxone was approved for U.S. sale in 2002, and Indivior had the exclusive right to sell the treatment in tablet form until 2009. States said Indivior switched to an oral film version of Suboxone from a tablet version to extend its monopoly, just as generic manufacturers were poised to sell their own lower-cost tablets. Generic tablets obtained federal approval in 2013. Indivior expects to pay the $102.5 million in cash this month.

Persons: drugmaker, Indivior, Suboxone, Josh Kaul, Mariam Sunny, Jonathan Stempel, Maju Samuel, Matthew Lewis Organizations: Indivior, D.C, U.S, U.S . Centers for Disease Control, Thomson Locations: Chesterfield , Virginia, U.S, Washington, Indivior's, Philadelphia, Suboxone, Wisconsin, United States, Bengaluru, New York

SummarySummary Companies Centrica, StanChart jump on upbeat earningsVodafone up on report exploring options for African UnitFTSE 100 up 0.2%, FTSE 250 flatFeb 16 (Reuters) - Britain's internationally-focussed FTSE 100 on Thursday closed above 8,000 points for the first time as upbeat earnings from Centrica and Standard Chartered countered global risk-off sentiment after hotter-than-expected U.S. inflation data. The blue-chip FTSE 100 (.FTSE) gained 0.2%, off an intra-day record high hit earlier in the day, but still at its highest ever closing level of 8,012.53 points. The exporter-heavy index has had a stellar start to the year, gaining 7.5% so far as positive corporate earnings and rising commodity prices supported the index. Data showed U.S. producer prices rose more than expected in January while jobless claims unexpectedly fell, fanning speculation the U.S. Federal Reserve would keep raising interest rates for longer than expected. Shares of Centrica (CNA.L) jumped to top the FTSE 100, adding 5.7%, after the British Gas owner's annual profit more than tripled and it announced an extension of its share buyback programme.

☆ FTSE 100 at record high on positive Centrica, StanChart earnings
▼ + stars: | 2023-02-16 | by ( Shashwat Chauhan | ) www.reuters.com time to read: +2 min

SummarySummary Companies FTSE 100 hits record high, trading above 8,000 pointsCentrica, StanChart, Relx jump on upbeat resultsVodafone rises on report of looking at options for Africa unitFTSE 100 up 0.3%, FTSE 250 adds 0.4%Feb 16 (Reuters) - UK's FTSE 100 rose to a record high on Thursday, underpinned by corporate earnings from Centrica and Standard Chartered, while higher commodity prices drove up heavyweight miners. The blue-chip FTSE 100 (.FTSE) gained 0.3%, trading comfortably above the 8,000-point mark it had breached in the previous session. The exporter-heavy FTSE has had a stellar start to the year as positive corporate earnings and rising commodity prices supported the index. Shares of Centrica (CNA.L) jumped to top the FTSE 100, adding 4.2%, after the British gas owner's annual profit more than tripled and as it announced an extension of its share buyback programme. Standard Chartered (STAN.L) rose 1.8% after the lender reported a 28% rise in annual pretax profit and unveiled a $1 billion share buyback programme.

☆ Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
▼ + stars: | 2023-01-26 | by ( ) www.reuters.com time to read: +2 min

Warren said that both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon’s Krystexxa, a gout medication. She noted that the FTC had settled with Indivior and its former parent over its attempt to protect its monopoly of the opioid addiction treatment Suboxone. Indivior makes Sublocade -- a slow-release treatment for opioid addiction that is administered monthly. "The FTC should strongly consider Indivior's history of anti-competitive and deceptive practices when evaluating howIndivior might behave after this potential transaction is completed," wrote Warren. Warren noted that the FTC, which has long focused on healthcare mergers, said in 2021 that it would prioritize pharmaceutical acquisitions.

☆ FTSE 100 rises on Informa boost; pound weakens
▼ + stars: | 2022-11-14 | by ( Shashwat Chauhan | ) www.reuters.com time to read: +2 min

SummarySummary Companies Media stocks lead sectoral gainsIndivior up on deal to buy Opiant PharmaUK budget, due later in the week, in focusFTSE 100 up 0.4%, FTSE 250 falls 1.2%Nov 14 (Reuters) - UK's export-oriented FTSE 100 climbed on Monday, lifted by events organiser Informa's over 5% jump and a weaker pound. The FTSE 100 (.FTSE) was up 0.4% by 0941 GMT. The company's announcement of raising its full-year earnings outlook pushed the broader FTSE 350 media index (.FTNMX403010) 1.0% higher. Among other stocks, Indivior (INDV.L) gained 0.9% after it said it would acquire Opiant Pharmaceuticals for approximately $145 million in cash. The domestically-focused FTSE 250 midcap index (.FTMC) dropped 1.2% after marking its biggest weekly gain in almost two years on Friday.

Search resuls for: "Indivior"

18 mentions found